UNIQURE N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.85 USD | -3.19% |
|
-0.61% | -28.36% |
| 05-08 | Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating | MT |
| 05-07 | UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 47.23M 51.32M 4.04B | Sales 2025 * | 83.38M 90.6M 7.12B | Capitalization | 217M 236M 18.52B |
|---|---|---|---|---|---|
| Net income 2024 * | -220M -239M -18.8B | Net income 2025 * | -171M -186M -14.61B | EV / Sales 2024 * | 3.12 x |
| Net cash position 2024 * | 69.35M 75.36M 5.93B | Net Debt 2025 * | 9.03M 9.81M 772M | EV / Sales 2025 * | 2.71 x |
| P/E ratio 2024 * |
-1.04
x | P/E ratio 2025 * |
-1.3
x | Employees | 480 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on uniQure N.V.
More recommendations
More press releases
| 1 day | -3.19% | ||
| 1 week | -0.61% | ||
| Current month | +9.98% | ||
| 1 month | +3.85% | ||
| 3 months | -22.40% | ||
| 6 months | -30.37% | ||
| Current year | -28.36% |
1 week
4.83
5.18
1 month
4.255.19
Current year
4.257.12
1 year
4.2521.88
3 years
4.2538.80
5 years
4.2582.49
10 years
4.2582.49
| Managers | Title | Age | Since |
|---|---|---|---|
Matt Kapusta
CEO | Chief Executive Officer | 51 | 31/12/14 |
Christian Klemt
DFI | Director of Finance/CFO | 51 | 31/12/14 |
Pierre Caloz
COO | Chief Operating Officer | 52 | 16/05/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Post
BRD | Director/Board Member | 72 | 16/06/20 |
Jack Kaye
BRD | Director/Board Member | 80 | 14/06/16 |
| Director/Board Member | 61 | 13/09/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 11 M€ | -6.03% | - | |
| 0.76% | 14 M€ | -2.76% | ||
| 0.48% | 28 M€ | -0.70% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/05/24 | 4.85 | -3.19% | 524,633 |
| 17/05/24 | 5.01 | -1.18% | 372,197 |
| 16/05/24 | 5.07 | +0.20% | 347,654 |
| 15/05/24 | 5.06 | +3.05% | 462,888 |
| 14/05/24 | 4.91 | +0.61% | 431,769 |
Delayed Quote Nasdaq, May 20, 2024 at 09:00 pm
More quotes
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.
Calendar
18/06/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
4.465
EUR
Average target price
18.07
EUR
Spread / Average Target
+304.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.36% | 235M | |
| +9.58% | 115B | |
| +12.41% | 107B | |
| -3.29% | 21.6B | |
| -12.38% | 22.31B | |
| -6.40% | 19.19B | |
| -3.35% | 18.23B | |
| -38.57% | 17.62B | |
| +7.51% | 14.26B | |
| +35.67% | 12.37B |
- Stock Market
- Equities
- QURE Stock
